GermanyGermany

Roche starts research cooperation for personalised treatment of chronic hepatitis

07.04.2011

Penzberg – Roche Diagnostics GmbH has joined in a cooperation with three partners from Spain to tailor personalised antiviral therapies against chronic infections with the hepatitis B and C viruses. The idea behind the collaboration with the Spanish Vall d’Hebron Institute of Research (VHIR), the Networking Biomedical Research Centre in Liver and Digestive Diseases (CIBEREHD), and the software producer Advanced Biological Laboratories Therapy Edge Spain (ABL) is to identify antiviral-resistant mutants early on in the virus populations and to tailor drug treatment to the individual virus subpopulation. The means for identifying the variable composition of virus subtypes will be Roche’s Next generation sequencing technology, together with other genetic and molecular analytical techniques. Infections with the hepatitis viruses can remain asymptomatic for decades before the disease has advanced and causes decompensated cirrhosis or hepatocellular carcinoma requiring liver transplantation in the worst case. An individualised early treatment of chronic hepatitis would offer huge savings for health care systems. Roche currently pioneers the field of sequencing-based molecular diagnostics. The firm is not too far from market launch in fields such as identification of drug resistant HIV resistance subtypes, HLA typing or even oncology.

Germany, FranceGermany

21.12.2011

Martinsried/Paris - Sanofi has done some Christmas shopping in Munich and has licensed Scil Technology’s programme for the regenerative treatment of osteoarthritis and cartilage disorders. Under the agreement, Scil could reap up...

GermanyGermany

20.12.2011

Monheim - It's nearly Christmas, and Bayer Crop Science gives out some presents. As the company announced, a $750 million settlement with U.S. rice farmers is now binding and can move forward. In summer the German firm had agreed...

GermanyGermany

16.12.2011

Bonn – Germany’s federal government is prolonging one of its most successful measures to date for stimulating the establishment of high-tech companies – the High-Tech-Gründerfonds (HTGF). The HTGF was launched in 2005 with €272m...

GermanyGermany

15.12.2011

Leverkusen – One short statement from the European Medicines Agency (EMA) means one giant step for German biotech company Biofrontera. The agency issued a favourable opinion on the firm’s marketing approval application for its...

GermanyGermany

15.12.2011

While the European sovereign debt crisis keeps capital markets in a choke-hold, with potential negative effects on the financing situation in many industries – including biotech – there was encouraging news for drug-developing...

GermanyGermany

08.12.2011

Heidelberg – There is still life in the European life science finance. EMBL Ventures has closed a €40m fund. The early stage investor and the venture capital arm of the European Molecular Biology Laboratory(EMBL) announced the...

GermanyGermany

03.11.2011

Düsseldorf – BIO-Europe 2011 in Düsseldorf has again broken all previous records in terms of participants and company numbers. More than 3,000 representatives from 1,800 companies registered for Europe‘s largest partnering event....

GermanyGermany

02.11.2011

Brussels/San Francisco – As the biggest biotech partnering event on the continent, BioEurope, draws to a close, the venture capital community sent ambivalent messages for life sciences. Dow Jones VentureSource, an analyst,...

Displaying results 11 to 20 out of 454

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-germany/browse/1/article/roche-starts-research-cooperation-for-personalised-treatment-of-chronic-hepatitis.html

Product of the week

Products

Events

All Events

Current issue

All issues